In addition to the driver KRAS mutations cells exhibit inactivation of tumor suppressors including CDKN2A, TP53, SMAD4 and PTEN as well as activation of PIK3CA that promote the progression and resistance of PDACs [39]. This evidence concerns the gene KRAS and neoplasm.